Extensive Drug-Resistant Salmonella Linked to Rosabella Brand Moringa Powder Capsules Prompts Nationwide and International Recall

The U.S. Food and Drug Administration (FDA) is alerting consumers and retailers to a recall of specific lots of Rosabella-brand moringa powder capsules due to a multistate outbreak of Salmonella Newport infections. The investigation, which is ongoing, has identified a Salmonella strain that is resistant to all commonly recommended first-line and alternative antibiotics, raising significant public health concerns.

The recalled product, Rosabella-brand moringa powder capsules, is packaged in white plastic bottles with a green label. Consumers and retailers are urged to check the expiration dates and lot codes on their bottles. Products with an expiration date in 2027 and specific lot codes are subject to the recall. A complete list of affected lot codes and their corresponding expiration dates is available. Ambrosia Brands, LLC, the distributor, initiated a recall of these lots on February 13, 2026. The contaminated product was distributed nationwide and also sold internationally through various online platforms, including eBay, TikTok Shop, Amazon, Shein, Etsy, and the Tryrosabella.com online store.

The outbreak investigation, a collaboration between the FDA, the Centers for Disease Control and Prevention (CDC), and state and local health partners, has reported seven cases of Salmonella infections across seven states: Arizona, Florida, Iowa, Illinois, Indiana, Tennessee, and Washington. Illnesses began between November 7, 2025, and January 8, 2026. Of the individuals interviewed, all reported consuming Rosabella-brand moringa powder capsules. Three hospitalizations have been reported, with no fatalities. The highly drug-resistant nature of the Salmonella strain poses a particular challenge for treatment, as it is resistant to standard antibiotic therapies. Healthcare providers are being advised on the specific resistance patterns of this strain and provided guidance for diagnosing and treating infections.

Consumers and retailers in possession of the recalled Rosabella-brand moringa powder capsules are instructed not to consume, sell, or distribute the product. Affected items should be discarded or returned to the place of purchase. Furthermore, thorough cleaning and sanitization of any surfaces or containers that may have come into contact with the recalled product are crucial to prevent cross-contamination. Individuals experiencing symptoms of Salmonella infection, which typically include diarrhea, fever, and abdominal cramps occurring within 12 to 72 hours of consumption, should seek immediate medical attention and inform their healthcare provider about their potential exposure to the recalled moringa capsules. Children under five, the elderly, and individuals with weakened immune systems are at higher risk for severe infections.

The FDA is actively conducting a traceback investigation to pinpoint the source of contamination and is collaborating with state agencies to collect samples for further analysis. As the investigation progresses, additional products may be identified as contaminated, and this public health advisory will be updated accordingly. The international distribution of the recalled product is extensive, with sales reported in numerous countries across North America, South America, Europe, Asia, Africa, and Oceania, in addition to U.S. territories.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration.

---